ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Quel est le ratio P/E de ANI Pharmaceuticals Inc (ANIP) ?
Le ratio P/E de ANI Pharmaceuticals Inc est de 23.3576
Qui est le CEO de ANI Pharmaceuticals Inc ?
Mr. Nikhil Lalwani est le President de ANI Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action ANIP ?
Le prix actuel de ANIP est de $78.71, il a 下降 de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de ANI Pharmaceuticals Inc ?
ANI Pharmaceuticals Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de ANI Pharmaceuticals Inc ?
La capitalisation boursière actuelle de ANI Pharmaceuticals Inc est de $1.7B
Est-ce que ANI Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 10 analystes ont établi des notations d'analystes pour ANI Pharmaceuticals Inc, y compris 5 achat fort, 7 achat, 2 maintien, 0 vente et 5 vente forte